BOSTON - BostonChron -- Philadelphia, PA – Mativa Diagnostics, an ultrasensitive biomarker IP-driven company, today announced a strategic partnership with UGenome AI to integrate advanced genomic and transcriptomic analytics into Mativa's rapidly expanding maternal health ecosystem. This collaboration aligns UGenome's vision of accessible genomic medicine with Mativa's focus on its MSight Diagnostic Device and MatBank biorepository.

A core pillar of this partnership is a commitment to the women driving maternal health research. Mativa will offer advanced genomic analysis as a free benefit to enrollees in the MatBank clinical study. By leveraging UGenome's expertise, Mativa is giving back to study participants, providing them clear, actionable health insights—a level of transparency and return value rarely seen in traditional trials.

Ahead of regulatory approval for its MSight Home Diagnostic Device Platform, Mativa will also offer genomic testing as a premium, fee-for-service feature on its upcoming MatHealth App. This will allow users to obtain comprehensive genomic analyses for themselves, their partner, and their children.

More on Boston Chron

• VMH Media Founder Vikki Jones Joins UGREEN at Gillette Stadium for Major Smart Living Launch
• CHUANG Stage Announces the 2026–27 Season: Reclaiming the Epics
• ChargeOn Announces Conversational Payment Management Solution
• King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
• Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center

This dual-pronged approach drives immediate fee-for-service revenue while incentivizing clinical enrollment. By layering UGenome AI's analytics over the massive clinical data generated through MatBank, Mativa is positioned to establish MatBank as a de-risked, valuable data asset for future therapeutic and diagnostic development. Dean Remy, the Co-Founder & COO/CCO states, "Mativa is redefining the maternal health landscape, not just in technology, but in how clinical trials are conducted. Partnering with UGenome allows us to give sensitive health data back to the women helping us build MatBank. Coupling this ethical approach to trial enrollment with a direct-to-consumer, fee-for-service offering in our MatHealth app demonstrates our commitment to immediate market impact and capital-efficient growth." UGenome Founder Zachary S. Brooks shares, "UGenome is thrilled to work with Mativa Diagnostics to support women and maternal health because it has such a huge benefit on everyone connected with material health: Everyone."

More on Boston Chron

• Boston: What's Your Swan Boat Story?
• Celebrating the Copley Plaza Hotel, Boston's New Landmark
• Boston: Be the Change: Public Art Comes to Historic Beacon Hill
• Boston: The New England Conservatory is a Landmark!
• Boston: Layers of Dorchester: Unearthing 190 Bowdoin Street

About Mativa Diagnostics

Mativa Diagnostics is an ultrasensitive detection, data & biomarker IP-driven company transforming maternal health. Mativa is advancing the MSight Pregnancy and Risk Factor Home Testing Platform designed to identify critical risk factors like ectopic pregnancy and preeclampsia with unparalleled sensitivity. By integrating proprietary physical diagnostics with the MatHealth App and the MatBank biorepository, Mativa is creating a uniquely valuable, longitudinal data asset that de-risks investment while providing proactive, comprehensive care pathways for women globally. Visit us at https://www.mativadx.com

About UGenome AI

UGenome is a multiomics software and analytics company dedicated to making genomic medicine more accessible. Through their Seq4Life™ and DNA2Health™ pharmacogenomic and wellness tools respectively, UGenome empowers clinicians and individuals with proactive actionable genomic insights across wellness, women's health, medication response, and broader health domains. For more info, visit ugenome.io.